[Non-peptide protease inhibitor in phase III study. Tipranavir--control of multidrug resistant viruses].
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000821:virology; D004305:Dose-Response Relationship, Drug; D024921:Drug Resistance, Multiple, Viral / Q000187:drug effects*; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D015337:Multicenter Studies as Topic; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D011753:Pyrones / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides; D014779:Virus Replication / Q000187:drug effects
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir